Docs biased against research from poor countries, study finds; Astellas probed over patient-assistance charity support; Acorda reports deaths in Parkinson's trial
Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head
No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.
FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi
The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial
Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose
Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study
Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.
In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer
Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.
The drugmaker is using Propeller Health's sensor technology to find new ways to improve adherence in clinical studies.
FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast
Jeanne Martel, president and partner at ClinicalMind, highlights her company's vision and role in communication and technology with MM&M's Jaimy Lee. This video was sponsored by ClinicalMind.
Certain insulins are comparable; Public Citizen criticizes Cures provision on orphan-drug exclusivity; the FDA approves Kanuma
Aggressive treatment of blood pressure reduces deaths; AstraZeneca's experimental lupus drug cut disease activity in trial; Sophiris Bio reports results for enlarged prostate drug
GSK partners with other drugmakers to bolster pipeline; Pfizer makes deal in South Africa for Prevnar 13; the FDA issues guidance on HIV biologic development
Therapy and low-dose drugs found to aid schizophrenia patients more than just antipsychotics; Clinton calls for investigations into drug price increases; Bayer issues RFP for AOR for consumer care brands
Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.
Sprout's controversial sexual-desire drug receives FDA approval; prescription-drug coverage impacts cash sales at Walmart; Mylan warned about manufacturing violations
Biogen to map ALS genes with Ice Bucket Challenge funds; Merck seeks first-line indication for Keytruda; lawmaker criticizes FDA approval of OxyContin for children
"Me-too" drugs may help lower costs; start-ups send doctors to your home; the FDA is likely to appeal the Amarin ruling
Genetic protein PD-L1 could have potential as a biomarker for a first-line treatment.
Physicians will be notified when patient care is not meeting national guidelines for COPD and asthma.
New data suggest Amgen's PCSK9 may reduce risks of heart attacks, Salix bidding is war too rich for Endo's blood, Actavis bipolar drug use is expanded to 10- to 17-year-olds.
Novartis CEO says cost cutting is looming; Novo Nordisk presents new Saxenda weight-loss data; FDA approves Astellas Pharma's antifungal drug.
The drugmakers will explore combinations of Merck's Keytruda and Eisai's Lenvima and Halaven to treat certain cancers.
The organization plans to publish a scientific and a lay abstract detailing study findings
Genentech Parkinson med encounters preliminary safety issues; Cigna gives Gilead's Harvoni preferred status over AbbVie's Viekira Pak; Valeant proposes $400 million bid to buy bankrupt Dendreon.